Assesses the value of a recombinant human interferon beta product AVONEX in delaying the onset of clinically definite multiple sclerosis (CDMS) in subjects who have experienced a first and recent onset of a demyelinating event involving the optic nerve, spinal cord, or brainstem/cerebellum, and who are at risk for MS based on the presence of multiple, magnetic resonance imaging (MRI) signal abnormalities in the brain.
Showing the most recent 10 out of 426 publications